{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl salicylate
to a specific field?
Class (Stereo):
CHEMICAL (ACHIRAL)
Tuvatidine (HUK 978) is a potent H2-antagonist. HUK 978 was shown to be devoid of activity at the histamine H1-receptor, the muscarinic receptor and the alpha and beta-adrenergic receptors. In both the guinea-pig gastric mucosa preparation and the rat perfused stomach
model, HUK 978 was a powerful inhibitor of acid secretion. HUK 978 is a highly specific H2-antagonist and inhibits acid secretion for longer periods than other competitive compounds.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Tamitinol (also known as EMD 21657), a neurotropic drug that was developed as a cognition enhancer for the treatment of diffuse cerebral disease and organic brain syndrome. Tamitinol participated in clinical trials where the therapeutic effects of the drug were shown to be statistically significant compared to placebo in the global response. However, the treatment was interrupted because of side effects (increased aggressiveness, rash) in 2 cases.
Status:
Investigational
Source:
NCT00411190: Phase 1 Interventional Completed Osteoarthritis
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Relacatib (SB-462795) is a potent and orally bioavailable small molecule inhibitor of cathepsin K that inhibits bone resorption. This has been shown in vitro in human tissue and in vivo in cynomolgus monkeys. The drug was developed for treatment in (postmenopausal) osteoporosis, osteoarthritis and potentially other bone disorders. Interactions with other drugs have been reported, and were subject of investigation of a phase I clinical trial (evaluating interactions of relacatib with ibuprofen, acetaminophen, and atorvastatin).
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Eticlopride {2S(−)-3-chloro-5-ethyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-hydroxy-2-methoxybenzamide} is an antagonist at dopamine D2 and D3 receptors. It is widely used for in vivo, in vitro, and ex vivo examination of D2/D3 receptors densities and function. Eticlopride exerts antipsychotic activity in animals.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Etisomicin is a semisynthetic aminoglycoside antibiotic.
Class (Stereo):
CHEMICAL (ACHIRAL)
Niometacin, an indometacin derivative, is a nonsteroidal anti-inflammatory drug.
Status:
Class (Stereo):
CHEMICAL (RACEMIC)
Dotefonium is the anticholinergic, spasmolytic agent.
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Prosulpride is an aminosulfonylbenzamide derivative with potent neuroleptic activity. Prosulpride selectively blocks the presynaptic dopaminergic receptors and antagonize apomorphine-induced stereotyped behavior, circling behavior, climbing behavior, increased motor activity and some other apomorphine-induced effects related to stimulation of postsynaptic dopaminergic receptors.
Class (Stereo):
CHEMICAL (RACEMIC)
Serfibrate, a clofibrate derivative, is a peroxisome proliferator activated receptor-α (PPAR-α) agonist. It is a hypolipidemic agent.
Status:
Investigational
Source:
NCT00296569: Phase 2 Interventional Completed Osteoarthritis
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MK-0686 is a bradykinin B1 receptor antagonist patented by American multinational pharmaceutical company Merck & Co for the treatment of neuropathic pain and inflammation. MK-0686 demonstrates significantly reduced susceptibility to human P-gp mediated efflux and shows good potential for human CNS penetration based on brain levels in CF-1 mice and monkeys. Additionally, MK-0686 also exhibited good CNS bradykinin B1 receptor occupancy in the transgenic rat expressing the human B1 receptor and showed oral efficacy in reducing CFA-induced hyperalgesia in a humanized mouse. Unfortunately, in phase II clinical trials MK-0686 failed to demonstrate efficacy in phase II clinical trials.
